natgillin/translations-raw huggingface dataset:
The method comprises: providing a reticulated foam substrate having at least one first surface for forming a side face of the filter and two opposed second surfaces for forming the through-flow faces of the filter; applying a liquid comprising an organic coating component to the first surface; solidifying the organic coating component to form a filter precursor having a volatilizable coating on the first surface; impregnating the filter precursor with a slurry comprising particles of a refractory material, a binder and a liquid carrier; and drying and firing the impregnated filter precursor to form the filter having a closed edge. 
Postupak proizvodnje vatrostalnog filtra od pjene sa zatvorenim rubom, koji obuhvaća: nabavu supstrata mrežaste pjene koja ima barem jednu prvu površinu za formiranje bočne strane filtra i dvije nasuprotne druge površine za formiranje protočnih strana filtra; nanošenje tekućine, koja sadrži komponentu organskog sloja, na prvu površinu; skrutnjavanje komponentne organskog sloja da se formira prekursor filtra koji ima kontinuiranu isparivu oblogu na prvoj površini; impregniranje prekursora filtra emulzijom za brušenje koja sadrži čestice vatrostalnog materijala, veziva i tekućeg nosača; i sušenje i paljenje impregniranog prekursora filtra radi formiranja filtra sa zatvorenim rubom.
Cylinder-piston system according to any one of the claims 1 to 5, characterized in that the compression set of the second polymer material (P) is in the range of 0 to 30 %, in particular in the range of in the range of 0 to 20 %, measured at 60° C. 
Sustav cilindar-klip prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što je skup kompresije drugog polimernog materijala (P) u rasponu od 0 do 30 %, naročito u rasponu od u rasponu od 0 do 20 %, mjereno pri 60° C.
in reaction (P-reac) the compound of formula (XXIV) is exposed to a temperature (P-temp); temperature (P-temp) is from 0 to 300 °C. 
Kod reakcije (P-reak.) spoj (XXIV) bude podvrgnut temperaturi (P-temp.); CH, CH, temperatura (P-temp.) iznosi 0 do 300*C.
After completion of the elution, the column was flushed with 3-5 BV of regeneration buffer containing EDTA. 
Nakon kompletiranja elucije, kolona je bila oprana s 3-5 BV regeneracijskog pufera koji sadrži EDTA.
The composition according to item 1, wherein said hydrophilic polymer is selected from the group consisting of starch, sodium carboxymethylcellulose, hydroxyethylcellulose, polyvinyl alcohol, sodium alginate, chitosan, and carrageenan. The composition according to item 1, wherein two polymers form the polymeric matrix, one of the polymers is an amphiphilic polymer and the other polymer is a hydrophilic polymer, said polymeric matrix is not crosslinked and no covalent interaction occurs between the two polymers. 
Kruti farmaceutski pripravak prema zahtjevu 1, koji sadrži dva lipofilna aktivna spoja, poželjno fenofibrat i atorvastatin, oba smještena u bliskom kontaktu s polimernom matricom, pri čemu navedena polimerna matrica nije poprečno povezana 1 ne dolazi do kovalentne interakcije između dva ili više polimera i između polimera i lipofilnih lijekova, navedena je matrica poželjno načinjena od dva polimera, jedan od polimera je amfifilni polimer, poželjno
The diluent may be present in a range of 10-80% by weight of the core. 
Razrjeđivač može biti prisutan u opsegu od 10 - 80 % po masi jezgre.
• R 19' and R 12 are the same or different and are linear alkyl, branched alkyl or cyclic alkyl having from 1 to 10 carbon atoms, or simple or substituted aryl or heterocyclic, and R 12 can in addition be H; 
• R19' i R12 su isti ili različiti i jesu nerazgranati alkil, razgranati alkil ili ciklički alkil s 1 do 10 atoma ugljika, ili nesupstituirani ili supstituirani aril ili heterocikl, a R12 dodatno može biti H;
The method according to claim 1, wherein after the rapid cooling, a targeted reheating of the seamless pipe wall takes place after further cooling of the pipe in air. 
Uređaj prema zahtjevu 1 do 4, naznačeno time da struja medija za hlađenje u zoni protoka hlađenja može biti uključen ovisno o položaju krajeva cijevi.
each A is independently selected from O, S and NR11; and each n is 0 or 1. 
Y? je dušik i R' je odsutan; i svaki n je 0 ili 1.
Contamination of extruded PMMA and/or ABS with even minimal traces of crosslinked PMMA compromises the technical and aesthetic characteristics of the product obtained, because of a behaviour which is not precisely thermoplastic, and more comparable to an inert. 
Kontaminacija ekstrudiranog PMMA i/ili ABS čak i s minimalnim tragovima umreženog PMMA kompromitira tehničke i estetske karakteristike dobivenog proizvoda, zbog ponašanja koje nije potpuno termoplastično, a može se više usporediti s inertnim.
(PS644) Example 3 This example details the pharmacokinetic properties of Fampridine-SR in tablets of the present invention administered to patients with multiple sclerosis. 
Sastav prema bilo kojem od zahtjeva 1 do 4, naznačen time da je postupak tretiranja multiple skleroze povećanje brzine hoda kod pacijenta s multiplom sklerozom.
The composite composition according to claim 5, wherein said network is added in amounts of 0.1 - 10 wt%, based on total polymer weight in the composite composition. 
Kompozicija kompozitnog materijala u skladu s patentnim zahtjevom 5, naznačena time što se navedena mreža dodaje u količinama od 0.1 - 10 tež%, na bazi ukupne težine polimera u kompoziciji kompozitnog materijala.
The pharmaceutical composition according to any of claims 1 to 5 being in a form selected from tablet, powder capsules, or formulated by dry granulation, slurries and dry roller compaction, preferably being in form of a tablet, most preferably being in form of a tablet producible obtainable by a direct compression process. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time da je u obliku koji je odabran od tablete, praškastih kapsula, ili je formuliran sa suhom granulacijom, tekućom suspenzijom i suhim sabijanjem valjkom, te je poželjno u obliku tablete, najpoželjnije je u obliku tablete koja se može proizvesti postupkom izravne kompresije.
A composition for use according to claim 1, further comprising at least one compound selected from sulfisoxazole, methimazole, prilocaine, dyphylline, quinacrine, carbenoxolone, aminocaproic acid, cabergoline, diethylcarbamazine, cinacalcet, cinnarizine, eplerenone, fenoldopam, leflunomide, levosimendan, sulodexide, terbinafine, zonisamide, etomidate, phenformin, trimetazidine, mexiletine, ifenprodil, moxifloxacin, bromocriptine or torasemide, or a pharmaceutically acceptable salt thereof. 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difiln, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
The compounds of the formula (I) in which R is H can be prepared from the corresponding phthalimido derivatives according to conventional procedures, e.g. 
Spojevi formule (I) u kojima je RH mogu se načiniti iz odgovarajućih ftalimido derivata prema konvencionalnim postupcima, npr.
If the animal survived longer than 30 days post-transplantation, the test and control articles were discontinued and the animal was allowed to continue until graft dysfunction or up to 100 days post-transplantation. 
Ukoliko je životinja preživjela dulje od 30 dana nakon transplantacije, testirani i kontrolni lijekovi su prekinuti i životinja je ostavljena da živi do disfunkcije transplantata ili do 100 dana nakon transplantacije.
withdrawing the slurry of expandable microspheres from the heating zone into a zone with a pressure sufficiently low for the microspheres to expand. 
(c) izvlačenju mulja od rastezljivih mikrosfera iz zone grijanja u zonu s tlakom dovoljno niskim da se mikrosfere ekspandiraju.
Detailed description of the invention 
Opis izuma u pojedinostima
wherein a redox cofactor is used in step b) and the redox cofactor is recycled by a cofactor regeneration system comprising a redox enzyme 
D-glukozon se enzimski reducira na D-fruktozu pomoću reduktaze, pri čemu se, osobito u koraku b), koristi redoks kofaktor.
Accordingly, embodiments of the present invention include: 
Broj objave europskog patenta:
(b1.2) sealing the opening thus obtained by way of a gas-impermeable film made of a multilayer preferably comprising a layer made of aluminum and a layer made of polypropylene; 
(b1.2) brtvljenje tako dobivenog otvora višeslojnim materijalom sloja koji sadržava sloj aluminija i sloj polipropilena;
Refrigerated display cabinet with a closing mechanism (1) according to any of the preceding claims, where the means for lateral displacement of the movable closing section (3) comprise laterally sliding elements (5) . 
Rashladna vitrina s mehanizmom za zatvaranje (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što element za bočno pomicanje pomičnog odjeljka za zatvaranje (3) sadrži bočno kližuće elemente (5).
The telomerase inhibitor for the use of claim 1, wherein the at least one symptom comprises shortness of breath, fatigue, weakness, fainting, nosebleeds, bruising, bleeding from mouth or gums, bloody stool, petechiae or stroke. 
Inhibitor telomeraze za uporabu u skladu s patentnim zahtjevom 1, naznačen time što najmanje jedan ublaženi simptom sadrži bol u kostima, umor, groznicu, noćno znojenje, gubitak u tjelesnoj težini, slabost, nesvjestica, krvarenje iz nosa, pojavu modrica, krvarenje iz usta ili desni, krvavu stolicu ili moždani udar.
The compound of formula (1) wherein: Q is a single bond, -O-, -S- or -N(R15)- wherein R15 is hydrogen, C1-3alkyl or C2-3alkanoyl or R15 and R1 together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring; 
Spoj formule (1): [image] naznačen time da: Q je jednostruka veza, -O-, -S- ili -N(R15)- pri čemu R15 je vodik, C1-3alkil ili C2-3alkanoil ili R15 i R1 zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten;
from about 20% to about 25% by weight on a dry weight basis of a pharmaceutically acceptable lactose; 
iii) od 20 do 25 masenih postotaka na bazi suhe mase farmaceutski prihvatljive laktoze;
The method according to claim 6, wherein the concentration of dissolved components in liquid solutions is reduced, in particular for water treatment or sea water desalination or the concentration of dissolved components in liquid solutions is increased, in particular for concentrating fruit juices. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 6 do 9, naznačen time što se koncentraciju otopljenih komponenata u tekućim otopinama smanjuje, osobito kod obrade vode ili odsoljavanja morske vode, ili se koncentraciju otopljenih komponenata u tekućim otopinama povećava, osobito kod koncentriranja voćnih sokova.
A pharmaceutical composition comprising a binding molecule or an antibody according to any one of embodiments Z1-9, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo sukladno bilo kojem od patentnih zahtjeva 1-9 1 farmaceutski prihvatljiv nosač.
the pharmaceutical preparation in the suitable container is an aqueous pharmaceutical solution which is a sterilized aqueous solution which has been sterilized by filtration and without subjecting the aqueous pharmaceutical solution to heat, chemicals, or radiation exposure; or 
Postupak prema bilo kojem od patentnih zahtjeva 1-12, naznačen time, da farmaceutski pripravak u prikladnom spremniku jest vodena farmaceutska otopina . koja je sterilizirana vodena otopina, koja je bila sterilizirana filtriranjem i bez podvrgavanja vodene farmaceutske otopine toplinskoj, kemijskoj ili radijacijskoj izloženosti.
The CPU-determined number of blocks is usually nonzero. 
Broj objave europskog patenta:
LDPC decoding the L1 signaling data and the de-punctured LDPC parity bits; 
LDPC dekodiranje signalnih podataka LI i zatvorenih LDPC paritetnih bitova; 1
The particular quantity of component (d) and/or (f) which can still be tolerated by the patient in the event of correct oral administration may be determined by the person skilled in the art by simple preliminary testing. 
Dotičnu količinu komponente (d) i/ili (f) koju pacijent kod propisane oralne primjene još tolerira, stručnjak može ustanoviti jednostavnim prethodnim pokusima.
programming said processor to execute instructions to process said vibration data from the at least one vibration sensor and said position as a function of time data from the transmitter of the movable object and compare the vibration data with the position as a function of time data, 
(i) omogućavanje najmanje jednog vibracijskog senzora (2, 12, 22, 22a, 22b, 32a, 32b, 32c, 42a, 42b, 42c, 52, 62) za raspoznavanje vibracije kao funkcije vremena;
to obtain the PLP from the signal frame using the layer-1 information, 
analiziranja okvira signala od primljenog signala ln nn na na nn nn
0221025, naphthyl analogs of mevalonolactone, as disclosed in U.S. Patent No. 
0221025, naftil analozi mevalonolaktona, kao što je navedeno u U.S. Patentu br.
Method in accordance with claim 1; characterised in that the method comprises a stage of heating the distribution agent to a temperature between 50° C. and 60° C. prior to the stage in which the distribution agent is added to the microwaveable popcorn package. 
Postupak u skladu s patentnim zahtjevom 1; naznačen time što se postupak sastoji u koraku grijanja sredstva za raspodjeljivanje do temperature između 50 "C 1 60 "C prije koraka u kojem se sredstvo za raspodjeljivanje dodaje pakiranju kojeg se može peći mikrovalovima.
The Mg2+ salt is particularly preferred. 
Mg"' sol je posebno prvenstvena.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound mandipropamid. 
CH, naznačen time da je Ry difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
The process according to claim 14, wherein the calcium carbonate is a ground natural calcium carbonate, a precipitated calcium carbonate, a modified calcium carbonate, or a mixture thereof. 
Postupak prema zahtjevu 14, gdje je kalcijev karbonat mljeveni prirodni kalcijev karbonat, taloženi kalcijev karbonat, modificirani kalcijev karbonat, ili njihova smjesa.
The opposite (in use lower) end of the latch sub extends towards the open, lower end of the housing and is threaded. 
Suprotni (pri korištenju donji) kraj elementa zasuna produžava se prema otvorenom donjem kraju kućišta i ima navoj.
The process of claim 2, wherein the organic solvent used in step ic is an aprotic solvent. 
Postupak prema zahtjevu 1, naznačen time što je prvo organsko otapalo aprotično otapalo.
granulating the active ingredient trituration of step (1) by adding the granulation liquid; 
(2) granuliranje triturata aktivnog sastojka iz koraka (1) dodavanjem granulacijske tekućine, povoljno je vode;
A pharmaceutical composition according to claim 11 or a preparation according to claim 12, wherein the other molecularly targeted agent is a conventional cytotoxic agent, or a compound used in postchemotherapy, stem-cell directed maintenance therapy and in MLL-rearranged infant acute lymphoblastic leukemia. 
Farmaceutski pripravak prema patentnom zahtjevu 11 1li pripravak prema patentnom zahtjevu 12, pri čemu je drugi molekularno ciljani agens uobičajeni citotoksični agens, ili spoj korišten u postkemoterapiji, terapiji održavanja upravljanoj matičnim stanicama te u MLL-presloženoj infantilnoj akutnoj limfoblastičnoj leukemiji.
The equipment for the pressing, for example, can be run hydraulically, pneumatically or optionally also with weights, and, for example, can be designed as a carousel or as a linear press. 
Oprema za prešanje, na primjer, može imati hidraulički pogon, pneumatski pogon ili po želji također i pogon s utezima i, na primjer, može biti izvedena kao kružna ili linearna preša.
(in the formula, Ts represents p-toluenesulfonyl and Me represents methyl). 
(u formuli Ts predstavlja p-toluensulfonil, a Me predstavlja metil).
Examples of similar methods can be found herein and in Nannini, G. et al. Eur. 
Primjeri sličnih postupaka mogu se pronaći ovdje i u Nannini, G. et al. Eur.
A compressed tablet comprising granules containing atazanavir sulfate and from 0.1 to 10% based on the total weight of the compressed tablet of an intragranular lubricant, said granules having an interior section and an exterior surface and wherein at least a portion of the intragranular lubricant is present in the interior section of the granules; wherein the intragranular lubricant is selected from the group consisting of magnesium stearate, zinc stearate, calcium stearate, stearic acid, palmitic acid, sodium stearyl fumarate, sodium benzoate, sodium lauryl sulfate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, carnauba wax, polyethylene glycol and mixtures thereof. 
HR P20140146 T1 PATENTNI ZAHTJEVI Komprimirana tableta sadrži granule s atazanavir sulfatom i od 0.1 do 10% intragranularnog lubrikanta u odnosu na ukupnu težinu komprimirane tablete, te granule imaju unutarnji dio i vanjsku površinu i gdje je barem dio intragranularnog lubrikanta prisutan u unutarnjem dijelu granula; pri čemu se intragranularni lubrikant izabire iz grupe koja obuhvaća magnezijev stearat, cinkov stearat, kalcijev stearat, stearinsku kiselinu, palmitinsku kiselinu, natrijev stearil fumarat, natrijev benzoat, natrijev lauril sulfat, gliceril monostearat, gliceril palmitostearat, hidrogenirano ricinusovo ulje, hidrogenirano biljno ulje, mineralno ulje, karnauba vosak, polietilen glikol i njihove mješavine.
the second fragment has a second proximal end; and wherein the first proximal end is within a short repeat and the second proximal end is within a short repeat; and wherein the first fragment and the second fragment are adjacent to one another and wherein the polypeptide elicits antibodies that neutralize toxin A and toxin B. 
proksimalni kraj drugog fragmenta se nalazi unutar drugog ponavljanog dijela; i gdje su prvi fragment i drugi fragment razdvojeni s manje od ili točno 5 aminokiselina u primarnoj strukturi, gdje polipeptid dovodi do pojave protutijela koja neutraliziraju toksin A i toksin B, te gdje su prvi ponavljani dio i drugi ponavljani dio imaju između sebe više od 50% istovjetnog slijeda.
glycosylation; and phosphorylation. 
(v) fosforilaciju.
The method of claim 2, wherein the Mtb72f is a polypeptide comprising residues 4-725 of SEQ ID NO:4. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što se sastoji od aminokiselinskog slijeda SEQ ID No: 4.
A process for preparing the article made of the multilayer composite material of claim 1, comprising: coating the first and second structural layers (A) with the thermosetting resin; 
Postupak priprave članka načinjenog od višeslojnog kompozitnog materijala u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u koracima:
The method of claim 1, wherein the CECs form a monolayer of uniformly sized cells, at least 50% of which exhibit a hexagonal shape. 
Postupak prema zahtjevu 1, naznačen time što CEC tvore monosloj stanica jednake veličine, od kojih se barem 50 % pojavljuje u heksagonalnom obliku.
The composition of claim 1 or 2, wherein said porogen hydrogel or said bulk hydrogel comprises a bioactive factor for use in promoting bone or cartilage repair, regeneration, or formation, wherein said bioactive factor optionally comprises BMP-2, BMP-4, or RunX. The composition of claim 10, wherein said porogen hydrogel or said bulk hydrogel 
Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni porogeni hidrogel ili navedeni volumni hidrogel sadrži bioaktivni čimbenik, namijenjen upotrebi u promicanju obnove, regeneriranja ili stvaranja kosti ili hrskavice, gdje navedeni bioaktivni čimbenik može uključivati BMP-2, BMP-4 ili RunX.
CHO-KI cells stably expressing the niacin receptor were used to make membrane for binding analysis. 
CHO-K1 stanice koje stabilno ekspresoniraju niacin receptor su korištene za dobivanje membrane za ispitivanje vezivanja.
Use of an ActRIIa-Fc fusion protein for the manufacture of a medicament for treatment or prevention of multiple myeloma in a human patient. An ActRIIa-Fc fusion protein for the use in the treatment or prevention of multiple myeloma in a human patient. 
Uporaba ActRIla-Fc fuzijskog proteina, naznačena time, što se koristi za izradu lijeka za liječenje ili prevenciju multiplog mijeloma kod humanog pacijenta, pri čemu je ActRIIa-Fc fuzijski protein onakav kako je definirano u bilo kojem od zahtjeva 1 do 10.
A process according to any one of claims 1 to 9, wherein the process further comprises manufacturing a tobacco extract from the treated tobacco material. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što se postupak dodatno sastoji u proizvodnji ekstrakta duhana iz obrađenog duhanskog materijala.
The effect of each concentration of test compound was quantified by expressing the tail current amplitude in the presence of a given concentration of test compound as a percentage of that in the presence of vehicle. 
Učinak svake koncentracije ispitivanog spoja kvantificiran je izražavanjem amplitude struje u prisutnosti dane koncentracije ispitivanog spoja kao postotka amplitude u prisutnosti nosača.
The genetically modified mouse of claim 1, wherein the endogenous λ light chain immunoglobulin locus comprises the endogenous mouse enhancer 2.4 or the endogenous mouse 3' enhancer. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što endogeni lokus imunoglobulina lakog lanca 2 sadrži endogeni mišji pojačivač 2.4 ili endogeni mišji 3' pojačivač.
Transdermal therapeutic system according to claim 1 containing less than 5% of penetration enhancers. 
Transdermalni terapijski sustav prema zahtjevu 1 naznačen time da sadrži manje od 5 % pojačivača penetracije.
The pharmaceutical composition or dosage form for use of any one of claims 1-4, wherein the molar ratio of trans-(-)-A9-tetrahydrocannabinol to trans-(+)-A9-tetrahydrocannabinol is within a range of from 0.8:1.2 to 1.2:0.8, preferably within a range of from 0.9:1.1 to 1.1:0.9, more preferably from 0.95:1.ops to 1.05:0.95 and most preferably 1:1. 
Farmaceutski sastav ili oblik doziranja za upotrebu prema bilo kojem zahtjevu od 1 do 4, naznačen time da je molarni omjer trans-(-)-A9-tetrahidrokanabinola prema trans-(+)-A9-tetrahidrokanabinolu unutar raspona od 0.8:1.2 do 1.2:0.8, poželjno unutar raspona od 0.9:1.1 do 1.1:0.9, poželjnije od 0.95:1.05 do 1.05:0.95 i najpoželjnije 1:1.
The reaction mixture was decanted, added to water (1500 ml), and then taken to pH1 with concentrated hydrochloric acid. 
Reakciona smjesa se dekantira, doda u vodu (15009 ml), 1 zatim podesi na pH 1 s koncentriranom klorovodičnom kiselinom.
The final blend thus obtained was compressed into 200 mg tablets on a tablet compression machine using 7.93 mm (10/32 inch) round flat bevel edged punches. 
Konačna mješavina dobivena na taj način komprimirana je u tablete od 200 mg na uređaju za kompresiju tableta rabeći 7,93 mm (10/32 inča) okrugle udarače ravnih rubova.
a combination of (1) a compound of the formula: 
(97) Broj objave europskog patenta:
A tablet composition containing a dihydrotetrabenazine of the invention is prepared by mixing the compound (25 mg) with iron oxide, lactose, magnesium stearate, starch maize white and talc, and compressing to form a tablet in known manner. Capsule Formulation 
Pripravak tablete koja sadrži dihidrotetrabenazin izuma je pripremljen miješanjem spoja (25 mg) sa željezo oksidom, laktozom, magnezij stearatom, bijelim kukuruznim škrobom i talkom, te komprimiranjem u oblik tableta na poznati način.
Characterisation of peptide agents of the invention 
Datum objave europskog patenta:
A compound of the formula (I) as claimed in claim 1, in which represents a heteroaryl group of the formula 
Spoj sa formulom (I) prema zahtjevu 1, naznačen time da predstavlja heteroarilnu skupinu sa formulom KS Bi